Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chicago, Illinois 60611


RATIONALE: High doses of esterified estrogens may stop the growth of breast cancer cells that no longer respond to hormone therapy. PURPOSE: This phase II trial is studying how well high-dose esterified estrogens work in treating postmenopausal women with metastatic breast cancer that has failed previous hormone therapy.

Study summary:

OBJECTIVES: Primary - Determine the clinical response rate in postmenopausal women with estrogen and/or progesterone receptor-positive metastatic breast cancer that has failed prior sequential endocrine therapy treated with high-dose esterified estrogens (Menest^®). Secondary - Determine time to disease progression in patients treated with this drug. - Determine the toxic effects of this drug in these patients. OUTLINE: Patients receive oral high-dose esterified estrogens (Menest^®) 3 times daily. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for 2 months. PROJECTED ACCRUAL: A total of 18-35 patients will be accrued for this study within 2 years.


DISEASE CHARACTERISTICS: - Histologically confirmed breast cancer - Metastatic disease - Documented disease progression - Must have received and subsequently failed (due to disease progression) ≥ 2 prior sequential endocrine therapies for treatment of metastatic breast cancer - Disease progression during adjuvant tamoxifen is considered 1 prior therapy - The 2 most recent treatments must have been endocrine agents - At least 1 objective measurable disease parameter - Brain metastases allowed provided both of the following criteria are met: - Brain metastases were previously treated AND are currently stable - Brain metastases are not the only site of metastatic disease - Hormone receptor status - Estrogen and/or progesterone receptor-positive tumor PATIENT CHARACTERISTICS: Age - 18 and over Sex - Female Menopausal status - Postmenopausal, as defined by any of the following: - At least 50 years of age with an intact uterus AND amenorrheic for the past 12 months - At least 50 years of age without a uterus AND follicle-stimulating hormone (FSH) level within postmenopausal range - Under 50 years of age and FSH level within postmenopausal range - Prior bilateral oophorectomy Performance status - ECOG 0-2 Life expectancy - At least 6 months Hematopoietic - Adequate hematologic function Hepatic - Adequate hepatic function - Bilirubin ≤ 1.5 times upper limit of normal - No history of hepatic adenoma Renal - Adequate renal function - No history of hypercalcemia or severe hypocalcemia Cardiovascular - No history of thrombophlebitis or thromboembolic disorders associated with prior estrogen use - No active thrombophlebitis or thromboembolic disorders - No history of uncontrolled hypertension Other - Not pregnant - No undiagnosed abnormal vaginal bleeding - No other serious medical illness - No psychiatric illness that would preclude giving informed consent - No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Prior chemotherapy for metastatic disease allowed - Prior adjuvant chemotherapy allowed Endocrine therapy - See Disease Characteristics Radiotherapy - Prior radiotherapy allowed provided the only site of measurable disease was not irradiated Surgery - Not specified



Primary Contact:

Principal Investigator
William J. Gradishar, MD
Robert H. Lurie Cancer Center

Backup Contact:


Location Contact:

Chicago, Illinois 60611
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.